Grzegorz Nowakowski, MD
Enriched profileConsultant and Professor of Medicine and Oncology, Division of Hematology; Vice Chair, Division of Hematology; Enterprise Deputy Director for Clinical Research, Mayo Clinic Comprehensive Cancer Center · Mayo Clinic
Grzegorz Nowakowski is Consultant and Professor of Medicine and Oncology, Division of Hematology; Vice Chair, Division of Hematology; Enterprise Deputy Director for Clinical Research, Mayo Clinic Comprehensive Cancer Center at Mayo Clinic. OpenAlex indexes 740 publications with 13,836 citations (h-index 65); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Grzegorz Nowakowski, MD, is Consultant and Professor of Medicine and Oncology, Division of Hematology at Mayo Clinic, Rochester, MN. The public record shows 740 publications with 13,836 citations (h-index 65), centered on Hematology. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 20 companies, 1 NIH-funded awards (2023–2025).
- Most recent indexed publication: 2026 · Blood cancer journal
- Top research focus: Hematology
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 20 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 42 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Voting member
FDA Oncology Drugs Advisory Committee (ODAC)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myleukemiateam.com ↗ - Co-Chair
ASH-FDA Regulatory Science Workshop
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →education.binaytara.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
Sponsor: Academic and Community Cancer Research United
- R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
Sponsor: Academic and Community Cancer Research United
Industry payments
Updated 27 Aug 2026
20 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202517 payments$21,049openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20259 payments$14,369openpaymentsdata.cms.gov ↗
- AstraZeneca UK LimitedProgram year20253 payments$13,295openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
97.8%SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor97.8%Remdesivir100%Part B, office-administered≥13 patientsCancer & immunology
1%Kinase inhibitor1%Imbruvica100%Part D<11 patientsDermatology
0.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor0.6%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2023–2025 per NIH RePORTER. The latest:
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.
Journal of clinical oncology
Clinical Trial2026 - Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma.
Clinical cancer research
Article2026
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/grzegorz-nowakowski-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Grzegorz-S-Nowakowski-38680568
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/gregnowakowski
Mentions by others
where others cite or feature them- Facebook
facebook.com/OncLive/videos/dr-nowakowski-on-the-implications-of-the-fda-approval-of-epcoritamab-in-follicul/1011458640992180
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Instagram
instagram.com/p/DJ8_bKwNAwR
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Other
alumniassociation.mayo.edu/colleague-notes/grzegorz-greg-nowakowski-m-d-vice-chair-division-of-hematology-mayo-clinic-in-rochester
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alumniassociation.mayo.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- M.D.
Medical University of Warsaw, Poland
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myleukemiateam.com ↗ - Internal medicine residency
Yale University Medical School-Norwalk Hospital, Norwalk, CT
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →education.binaytara.org ↗ - Fellowship
Hematology and Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myleukemiateam.com ↗ - Board Certified
Hematology, American Board of Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myleukemiateam.com ↗ - Board Certified
Medical Oncology, American Board of Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myleukemiateam.com ↗
Editorial & leadership roles
journal and society appointments- Chair
American Society of Hematology (ASH) Clinical Trial Innovation Subcommittee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →education.binaytara.org ↗ - Chair
American Society of Clinical Oncology (ASCO) Clinical Trial Access and Participation Taskforce
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →education.binaytara.org ↗ - Aggressive B-cell Lymphoma Program Director; Chairman of Education; Advanced Hematology Fellowship Program Director
Mayo Clinic Division of Hematology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mcpress.mayoclinic.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bloodcancerunited.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bloodcancerunited.org ↗
Secondary affiliations
appointments beyond the home institution- Member
ECOG-ACRIN Lymphoma Core Committee (cooperative group clinical trials)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →education.binaytara.org ↗ - Chair
Lymphoma Committee and Hematological Malignancy Program, Academic and Community Cancer Research United (ACCRU) network
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bloodcancerunited.org ↗
Media & interviews
press, podcasts and appearances- Podcast guest
"Clinical Trials in Lymphoma: An Evolution, Not A Revolution," The Bloodline with Blood Cancer United (formerly LLS), episode 100
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →thebloodline.org ↗ - Recurring video contributor/author
OncLive oncology news video interviews
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - Featured speaker
PeerView Clinical Pharmacology CME video "Raising Frontline Expectations in DLBCL"
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podscan.fm ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Rick Nishimura, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic